Subjects -> MEDICAL SCIENCES (Total: 8185 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - DENTISTRY (266 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (177 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 151 of 151 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 2)
Acta Haematologica     Full-text available via subscription   (Followers: 23)
Acta Haematologica Polonica     Open Access  
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 52)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 15)
Archives of Hematology Case Reports and Reviews     Open Access  
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 29)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 4)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 296)
Blood Advances     Open Access   (Followers: 7)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 18)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 8)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 60)
Blood Pressure     Open Access  
Blood Pressure Monitoring     Hybrid Journal   (Followers: 1)
Blood Purification     Full-text available via subscription   (Followers: 6)
Blood Reviews     Hybrid Journal   (Followers: 26)
BMC Hematology     Open Access   (Followers: 7)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 29)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 17)
British Journal of Diabetes & Vascular Disease     Open Access   (Followers: 21)
British Journal of Haematology     Hybrid Journal   (Followers: 60)
British Journal of Primary Care Nursing - Cardiovascular Disease, Diabetes and Kidney Care     Full-text available via subscription   (Followers: 10)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 28)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 32)
Clinical Diabetes     Full-text available via subscription   (Followers: 39)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 20)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Clinical Lymphoma Myeloma and Leukemia     Hybrid Journal   (Followers: 5)
Clinical Medicine Insights : Blood Disorders     Open Access   (Followers: 1)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 3)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 24)
Current Diabetes Reviews     Hybrid Journal   (Followers: 27)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 20)
Cytotherapy     Full-text available via subscription   (Followers: 2)
Der Diabetologe     Hybrid Journal   (Followers: 2)
Diabetes     Full-text available via subscription   (Followers: 410)
Diabetes aktuell     Hybrid Journal   (Followers: 3)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 20)
Diabetes Care     Full-text available via subscription   (Followers: 469)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 27)
Diabetes Management     Full-text available via subscription   (Followers: 15)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 70)
Diabetes Spectrum     Full-text available via subscription   (Followers: 16)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 50)
Diabetes Therapy     Open Access   (Followers: 23)
Diabetic Foot & Ankle     Open Access   (Followers: 10)
Diabetic Medicine     Hybrid Journal   (Followers: 147)
Diabetologia     Hybrid Journal   (Followers: 205)
Diabetologia Kliniczna     Hybrid Journal  
Diabetologie und Stoffwechsel     Hybrid Journal   (Followers: 2)
Egyptian Journal of Haematology     Open Access  
eJHaem     Open Access  
European Journal of Haematology     Hybrid Journal   (Followers: 16)
Experimental Hematology     Hybrid Journal   (Followers: 6)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 5)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Global Journal of Transfusion Medicine     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 33)
Haemophilia     Hybrid Journal   (Followers: 66)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematología     Open Access  
Hematology     Open Access   (Followers: 15)
Hematology Reports     Open Access   (Followers: 4)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hematology/Oncology and Stem Cell Therapy     Open Access   (Followers: 6)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 1)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 2)
Info Diabetologie     Full-text available via subscription   (Followers: 1)
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access  
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 6)
International Journal of Diabetes Research     Open Access   (Followers: 8)
International Journal of Hematologic Oncology     Open Access   (Followers: 2)
International Journal of Hematology     Hybrid Journal   (Followers: 4)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Hematology-Oncology and Stem Cell Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 25)
Iraqi Journal of Hematology     Open Access  
JMIR Diabetes     Open Access  
Journal of Blood Disorders & Transfusion     Open Access   (Followers: 3)
Journal of Applied Hematology     Open Access   (Followers: 2)
Journal of Blood Medicine     Open Access   (Followers: 1)
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 20)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 25)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 8)
Journal of Diabetes Investigation     Open Access   (Followers: 12)
Journal of Diabetes Mellitus     Open Access   (Followers: 5)
Journal of Diabetes Research     Open Access   (Followers: 13)
Journal of Diabetes Research     Open Access   (Followers: 9)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology     Open Access   (Followers: 2)
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Hypo & Hyperglycemia     Partially Free  
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 8)
Journal of Social Health and Diabetes     Open Access   (Followers: 1)
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 81)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 35)
Journal of Transfusion Medicine     Full-text available via subscription  
Kidney and Blood Pressure Research     Open Access   (Followers: 4)
Leukemia     Hybrid Journal   (Followers: 22)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 12)
Leukemia Research     Hybrid Journal   (Followers: 8)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Mediterranean Journal of Hematology and Infectious Diseases     Open Access  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 20)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 8)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Platelets     Hybrid Journal   (Followers: 3)
Practical Diabetes     Hybrid Journal   (Followers: 7)
Primary Care Diabetes     Hybrid Journal   (Followers: 26)
Research & Reviews : Journal of Oncology and Hematology     Full-text available via subscription   (Followers: 1)
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 1)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 12)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 45)
Thalassemia Reports     Open Access   (Followers: 1)
The Lancet Haematology     Full-text available via subscription   (Followers: 38)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 145)
Thrombosis Research     Hybrid Journal   (Followers: 47)
Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie     Hybrid Journal  
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 13)
Veins and Lymphatics     Open Access   (Followers: 1)


Similar Journals
Journal Cover
Acta Haematologica Polonica
Journal Prestige (SJR): 0.128
Number of Followers: 0  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0001-5814 - ISSN (Online) 2300-7117
Published by Via Medica Homepage  [41 journals]
  • Assessment of two main therapeutic regimens of chronic lymphocytic
           leukemia in a major referral center in Syria

    • Authors: Lujain Hamdan, Firas Hussein, Samer Akel
      Abstract: Introduction: Due to the high cost of targeted therapy, chemoimmunotherapy regimens remain the standard therapy for chronic lymphocytic leukemia in many developing countries. In this study, we compare the treatment outcomes of the two main chemoimmunotherapeutic regimens. Material and methods: Data was obtained from the oncology department archives at Tishreen University Hospital between 2016 and 2020. We enrolled previously untreated, fit patients with chronic lymphocytic leukemia who were treated with one of two regimens: either a fludarabine, cyclophosphamide, and rituximab regimen, or a bendamustine and rituximab regimen. Results: 78 patients were enrolled in the study. 56.8% of the fludarabine, cyclophosphamide, and rituximab group achieved complete response versus 73.5% of the bendamustine and rituximab group. Progression-free survival was slightly shorter for fludarabine, cyclophosphamide, and rituximab than for bendamustine and rituximab [median 15.1 months [95% confidence interval {CI} 12.4–17.8] vs. 17.7 months (95% CI 15.4–20.1)] without statistical significance. In elderly patients (>65 years) median progression-free survival (PFS) was significantly (p = 0.046) longer with the bendamustine and rituximab treatment [median 19.9 months (95% CI 17.2–22.5)] than with the fludarabine, cyclophosphamide, and rituximab [median 11.6 months (6–17.2)]. Regarding overall survival, no significant difference between the two groups was documented. Delay and deletion of cycles, neutropenia and anemia were more frequent with the fludarabine, cyclophosphamide, and rituximab group. Furthermore, we found that elevated lactate dehydrogenase, positive expression of ZAP-70, stage C, and splenomegaly are all indicators of poor prognosis in correlation with PFS. Conclusions: Our study found that the bendamustine and rituximab regimen is safer than, and has comparable efficacy to, the standard therapy of fludarabine, cyclophosphamide, and rituximab for previously untreated, fit patients with chronic lymphocytic leukemia.
      PubDate: 2022-08-07
      Issue No: Vol. 53 (2022)
  • Single insult origin of Paget-Schroetter syndrome in adolescent
           successfully treated with balloon angioplasty and AngioJet thrombectomy

    • Authors: Remigiusz Krysiak, Jarosław Żyłkowski, Vadym Matsibora, Paweł Łaguna, Michał Brzewski
      PubDate: 2022-08-05
      Issue No: Vol. 53 (2022)
  • Neutropenic enterocolitis and multidrug-resistant bacteria colonization in
           lymphoma patients undergoing autologous stem cell transplantation

    • Authors: Monika Joks, Joanna Rupa-Matysek, Magdalena Matuszak, Anna Łojko-Dankowska, Lidia Gil
      Abstract: Introduction: There is little iterature data regarding neutropenic enterocolitis (NE) development after autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL) patients. The aim of this study was to determine the incidence, risk factors, and clinical outcome of NE after auto-HCT in NHL patients with respect to the impact of multidrug-resistant Gram-negative bacteria (MDRG) and vancomycin-resistant enterococci colonization on the early outcome after auto-HCT. Material and methods: This retrospective single-center analysis included a total of 65 NHL patients who underwent auto-HCT after BEAM (BCNU, etoposide, cytosine arabinoside, melphalan) conditioning (BEAM-auto-HCT). Results: NE was diagnosed in nine (13.8%) patients, a median four days after auto-HCT. In 6/9 (66%) patients, septic shock following NE was diagnosed. In univariate analysis, MDRG colonization before BEAM-auto-HCT was the only factor significant for NE development [odds ratio (OR) 2.4 (1.14–5.0), p = 0.027], although this was not confirmed in multivariate analysis. Additionally, NE [OR 5.2 (1.9–13.9), p = 0.001] and MDRG colonization prior to transplant [OR 2.7 (1.0–7.0), p = 0.041] were independent factors for septic shock development. Conclusions: Our findings suggest that NHL patients presenting with MDRG colonization before transplant should be kept under careful surveillance because of the high risk of the development of early severe infectious complications, including abdominal ones.
      PubDate: 2022-08-04
      Issue No: Vol. 53 (2022)
  • In seeking diagnostic tool for laboratory monitoring of FXII-targeting
           agents, could assessment of rotational thromboelastometry (ROTEM) in
           patients with factor XII deficiency be useful'

    • Authors: Paulina Stelmach, Weronika Nowak, Marta Robak, Emilia Krzemińska, Marzena Tybura-Sawicka, Krzysztof Chojnowski, Jacek Treliński
      Abstract: Introduction: Targeting factor XII (FXII) is a new concept for safe thrombosis prophylaxis. Global hemostasis tests offer promise in terms of the laboratory monitoring of FXII inhibition. The present study examines selected parameters of rotational thromboelastometry (ROTEM) in patients with FXII deficiency. The objective of this study was to assess the impact of FXII deficiency on selected parameters of ROTEM, which can be significant in the laboratory monitoring of FXII inhibition. Material and methods: The study included 20 patients with FXII deficiency ≤40% and 21 volunteers free of it. Clotting time (CT), clot formation time (CFT), alpha angle (α), maximum clot firmness (MCF), and maximum lysis (ML) were recorded in ROTEM. Results: For the INTEM test, CT and CFT readings were markedly higher in FXII deficient patients than in controls. No marked differences in relation to MCF and ML were found. Conclusion: The results of ROTEM show that FXII deficiency has a great impact on the initiation and amplification of coagulation. This was confirmed by a number of marked correlations between FXII activity and certain ROTEM parameters. ROTEM tests merit further investigation as treatment control strategies in the context of FXII inhibition.
      PubDate: 2022-08-04
      Issue No: Vol. 53 (2022)
  • Double transformation of relapsing juvenile myelomonocytic leukemia to
           refractory acute myeloid leukemia

    • Authors: Tomasz Styczyński, Jagoda Sadlok, Monika Richert-Przygońska, Robert Dębski, Małgorzata Kubicka, Beata Kuryło-Rafińska, Krzysztof Czyżewski
      PubDate: 2022-08-04
      Issue No: Vol. 53 (2022)
  • Supportive care in multiple myeloma

    • Authors: Artur Jurczyszyn, Grzegorz Charliński, David H. Vesole
      Abstract: Multiple myeloma is one of the most commonly diagnosed blood cancers. Due to the introduction of new therapies in recent years, there has been significant progress in treating myeloma. Even so, with the introduction of new groups of drugs, there have been some adverse events. In addition to anti-myeloma treatment, patients require supportive therapies. This article presents the principles of supportive treatment in emergencies and discusses the toxicity associated with the use of new groups of drugs.
      PubDate: 2022-08-01
      Issue No: Vol. 53 (2022)
  • A living drug: application of CAR-T therapy for lymphoid malignancies and

    • Authors: Anna Strzelec, Anna Klima, Natalia Gawlik-Rzemieniewska, Grzegorz Helbig
      Abstract: The ongoing development of novel personalized cancer therapies has resulted in the implementation of T cells enriched with synthetic chimeric antigen receptors, known as chimeric antigen receptors T cell (CAR-T) cells, into clinical practice. CAR-T cells are able to recognize and bind specific antigens present on the surface of target cells — so-called tumor-associated antigens. This innovative method has been approved for the treatment of hematological malignancies and may also serve as a bridge to hematopoietic stem cell transplantation. The production of the drug containing modified T cells consists of several steps — leukapheresis, T cell activation, transduction and expansion of the final CAR-T cells. Activation of CAR-T cells occurs through a pathway independent of the major histocompatibility complex, which is often associated with uncontrolled responses from the immune system and adverse reactions such as cytokine release syndrome. CAR-T therapy can only be performed in certified centers, and requires close cooperation between experienced specialists of different medical disciplines. This is what determines its effectiveness. Every step from collection and cryopreservation, through transport and modification, to thawing and infusion is strictly controlled because it has a critical impact on the quality and efficiency of the drug. Despite its proven benefits, CAR-T therapy remains available only to patients who meet well-defined criteria. These however are liable to change with the emergence of new indications.
      PubDate: 2022-07-28
      Issue No: Vol. 53 (2022)
  • Ruxolitinib-associated squamous cell carcinoma

    • Authors: Miguel Alpalhão, Luís Soares-Almeida, Paulo Filipe
      PubDate: 2022-07-28
      Issue No: Vol. 53 (2022)
  • Characteristics of COVID-19 in pediatric patients with hematological

    • Authors: Olga Troyanovska, Olga Dorosh, Halyna Lytvyn, Iryna Tsymbalyuk, Oxana Vorobel, Olena Stepanyuk, Hrystyna Bodak, Olena Kozlova, Mariya Stasiv, Nata Basiv
      Abstract: Introduction: As more data is collected, hematologists will be able to gain more insight into the impact of coronavirus disease 2019 (COVID-19) on pediatric patients with hematological malignancies. Material and methods: We analysed 21 cases of COVID-19 in pediatric patients with onco-hematological diseases treated in the Western Ukrainian Pediatric Medical Center from March 2020 through May 2021. The majority of patients (71.4%) were diagnosed with acute lymphoblastic leukemia. All patients from the analyzed cohort had an asymptomatic, mild or moderate course of coronavirus-19 infection. The most common symptoms of COVID-19 were fever, cough, gastrointestinal symptoms, and dermatitis. Severe severe acute respiratory syndrome coronavirus 2 increased the risk of liver toxicity and venous thrombosis. Results and conclusion: Our analysis showed that pediatric patients with hematological malignancies need the same treatment approach for COVID-19 as for other infective complications.
      PubDate: 2022-07-25
      Issue No: Vol. 53 (2022)
  • Standardizing blood dose using body surface area and analyze the effect of
           blood storage on hemoglobin increment within pediatric patients

    • Authors: Sankalp Sharma, Sunil Jondhale, Mili Patel, Arvind Shukla, Anil Goel
      Abstract: Introduction: Pediatric patients exhibit a wide variation in weight which results in diverse transfusion practices. This study aims to standardize red blood cell (RBC) doses according to body surface area (BSA) and to analyze the role of RBC storage in post-transfusion hemoglobin levels. Material and methods: In this original prospective cohort study on hospitalized pediatric patients aged up to 14, we classified patients into transfusion-dependent (n = 31) and non-transfusion-dependent (n = 158). The non-transfusiondependent group was further classified into ≤10 kg (n = 72) or >10 kg (n = 86) according to body weight (bw). We derived a regression equation between BSA and blood dose in non-transfusion-dependent subjects, and modified the equation by fixing blood dose to 15 mL/kg bw for only BSA based blood dose. We measured pre-transfusion and post-transfusion hemoglobin (Hb) levels, and ascertained effects of blood storage ≤15 days (n = 15) and >15 days (n = 16) on posttransfusion Hb. Results: Pediatric patients ≤10 kg and >10 kg bw (n = 158); mean ± standard deviation of weight and BSA were 4.5 ± 3.1 kg; 22.9 ± 10.4 kg; 0.26 ± 0.14 m2; 0.9 ± 0.28) m2 respectively. The regression equation ≤10 kg and >10 kg bw when adjusted. Blood dose fixed at 15 mL/kg bw adjusted blood dose ≤10 kg; 15 mL/kg bw = −19.12 + 329.69x BSA m2. The regression equation >10 kg bw: adjusted blood dose >10 kg bw; 15 mL/kg bw = −158.8 + 563.3x BSA (m2). The adjusted blood dose with BSA did not exceed 20 mL/kg bw. No significant differences were observed in pre and post-transfusion Hb in transfusion-dependent (n = 31) versus non-transfusion-dependent patients (n = 158) due to the RBC storage duration. Conclusions: RBC blood dose can be standardized by regression equation between standardized RBC dosage and BSA. Post-transfusion Hb is not dependent on days of RBC storage at the blood bank.
      PubDate: 2022-06-05
      Issue No: Vol. 53 (2022)
  • Anemia of critical illness: a narrative review

    • Authors: Piotr F. Czempik, Łukasz J. Krzych
      Abstract: The prevalence of anemia in patients admitted to the intensive care unit (ICU) reaches 66%. Moreover, numerous patients develop anemia during ICU hospitalization. In fact, anemia is the most common hematologic disease in the ICU. The majority of patients hospitalized in the ICU present with acute systemic inflammation, so called systemic inflammatory response syndrome (SIRS). These patients may develop anemia of inflammation (AI). In crtitically ill patients AI may present acutely (acute systemic inflammation) or chronically (comorbidities associated with prolonged systemic inflammation), here we describe both presentations of AI as ‘anemia of critical illness’ (ACI). The second most frequent type of anemia in critically ill patients is iron-deficiency anemia (IDA). A mixed type of anemia (ACI + IDA) may also be present in these patients. The three major pathophysiological mechanisms leading to ACI are: iron restriction, decreased erythropoiesis, and
      decreased erythrocyte lifespan. Cytokines synthesized during SIRS induce the production of hepcidin that inhibits the
      only transmembrane iron exporter (ferroportin) present in the duodenum and macrophages. Etiological classification of anemia in critically ill patients poses a significant challenge to clinicians, as there is a multitudeof tests available, and there are various reference ranges for these tests reported in the literature in the patient population in question. Pure ACI or mixed ACI + IDA can be diagnosed using a single laboratory test — complete blood count with analysis of reticulocytes — which provides Hb concentration in erythrocyte and reticulocyte. The management of ACI incorporates discontinuation with erythropoiesis-stimulating agent causing anemia, reduction
      of iatrogenic blood loss, parenteral iron, and combined therapy of parenteral iron with erythropoiesis-stimulating
      agents in approved indications.
      PubDate: 2022-05-16
      Issue No: Vol. 53 (2022)
  • Tribute to Anna Waszczuk-Gajda

    • Authors: Joanna Drozd-Sokołowska
      Issue No: Vol. 53
  • 30th Congress of the Polish Society of Haematologists and
           Transfusiologists: in the shadow of international conflicts

    • Authors: Jan Styczyński
      Issue No: Vol. 53
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-